AITL develops via a multistep oncogenic pathway involving frequent RHOA mutations as well as recurrent mutations in the epigenetic modifier genes, e.g., TET2, DNMT3A, and IDH2. This evidence concerns the gene IDH2 and angioimmunoblastic T-cell lymphoma.